“Lest we forget you - methylene blue …”
Methylene blue (MB), the first synthetic drug, has a 120-year-long history of diverse applications, both in medical treatments and as a staining reagent. In recent years there was a surge of interest in MB as an antimalarial agent and as a potential treatment of neurodegenerative disorders such as A...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Article (Journal) |
| Langue: | anglais |
| Publié: |
12 February 2011
|
| In: |
Neurobiology of aging
Year: 2011, Volume: 32, Numéro: 12, Pages: 2325.e7-2325.e16 |
| ISSN: | 1558-1497 |
| DOI: | 10.1016/j.neurobiolaging.2010.12.012 |
| Accès en ligne: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.neurobiolaging.2010.12.012 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0197458010005294 
|
| Notes sur l'auteur: | R. Heiner Schirmer, Heike Adler, Marcus Pickhardt, Eckhard Mandelkow |
| Résumé: | Methylene blue (MB), the first synthetic drug, has a 120-year-long history of diverse applications, both in medical treatments and as a staining reagent. In recent years there was a surge of interest in MB as an antimalarial agent and as a potential treatment of neurodegenerative disorders such as Alzheimer's disease (AD), possibly through its inhibition of the aggregation of tau protein. Here we review the history and medical applications of MB, with emphasis on recent developments. |
|---|---|
| Description: | Gesehen am 11.10.2022 |
| Description matérielle: | Online Resource |
| ISSN: | 1558-1497 |
| DOI: | 10.1016/j.neurobiolaging.2010.12.012 |